Eli Lilly’s Stock Price Should Continue To Fall Further (Seeking Alpha Article)

Please share/like us:

Summary

  • Failure of trial III Alzheimer drug, Solanezumab, is a major setback for Eli Lilly.
  • Lilly’s spending relative to the industry is following the same pattern as in 2005 and 2007, before its stock price got cut in half in over a year.
  • While Lilly is strengthening its pipeline in the diabetes space, it will not be enough to stop the stock from continuing to fall as they face stiff competition.
  • Four drugs accounting for 29.6%, or almost $1.5 billion of its third-quarter sales, are due to lose their compound protection this month and next year.

To keep reading more, the article is available on Seeking Alpha. Or copy/paste: http://seekingalpha.com/article/4032921-eli-lillys-stock-price-continue-fall.

Please share/like us:

Author: Khojinur Usmonov

A student at Baruch College (CUNY) in NYC, majoring in economics. Double minor in Business Writing and Data Analytics. Starting trading forex at age 15. Started investing in equities at age 17. Currently 20 years old and trade three asset classes; forex, equities, and commodities. Twitter: @Khojinur30

Leave a Reply

Your email address will not be published. Required fields are marked *

*